Glax­o­SmithK­line's lat­est makeover in­cludes auc­tion­ing off der­ma­tol­ogy, adding new tech and lay­offs. But how many?

GSK ex­ecs an­nounced Wednes­day morn­ing that they are set­ting up a 2-year pro­gram to pre­pare the com­pa­ny for its split in two — con­sumer health­care and the R&D-fo­cused out­fit she and re­search chief Hal Bar­ron promised to re­vamp and reen­er­gize 2 years ago.

A key part of that ef­fort is a new R&D re­or­ga­ni­za­tion in which the vac­cines group — tra­di­tion­al­ly sep­a­rate in­side the glob­al or­ga­ni­za­tion — will in­te­grate its work with the phar­ma teams in or­der to or­ches­trate com­mon re­search themes on both sides. And GSK is help­ing pay for the 2-year pro­gram with a plan to sell off non-core as­sets, start­ing with its der­ma­tol­ogy drugs port­fo­lio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER